viernes, 15 de octubre de 2021

Phase 1 open-label trial shows SARS-CoV-2 DNA vaccine induces durable immune response

Phase 1 open-label trial shows SARS-CoV-2 DNA vaccine induces durable immune response

No hay comentarios:

Publicar un comentario